-+ 0.00%
-+ 0.00%
-+ 0.00%

Leads Biolabs wins China IND approval for Opamtistomig combo trial in metastatic colorectal cancer

PUBT·08/03/2026 03:43:44
Listen to the news
Leads Biolabs wins China IND approval for Opamtistomig combo trial in metastatic colorectal cancer
  • Nanjing Leads Biolabs received NMPA CDE clearance for an IND to start an open-label Phase Ib/II trial in metastatic colorectal cancer.
  • The study tests Opamtistomig (LBL-024), a PD-L1/4-1BB bispecific antibody, in combination regimens to assess safety and efficacy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608022343PRIMZONEFULLFEED9802307) on August 03, 2026, and is solely responsible for the information contained therein.